You are here

A Study Comparing The Effects Of Epoetin Hospira Single-Dose Vial (SDV) And Multi-Dose Vial (MDV) When Administered Subcutaneously To Normal Healthy Subjects

Last updated on May 18, 2018

FOR MORE INFORMATION
Study Location
Pfizer New Haven Clinical Research Unit
New Haven, Connecticut, 06511 United States
Contact
1-800-254-6398
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Healthy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Healthy female and male subjects who, at time of Screening, are between ages of 18 and
55 years, inclusive. Healthy is defined as no clinically relevant abnormalities
identified by a detailed medical history, full physical examination including blood
pressure and pulse rate measurement, 12-lead electrocardiogram, or clinical laboratory
tests.

Female subjects of nonchildbearing potential must meet at least 1 of the following
criteria:

1. Achieved postmenopausal status, defined as follows: cessation of regular menses
for at least 12 consecutive months with no alternative pathological or
physiological cause; a serum follicle-stimulating hormone (FSH) level confirming
the postmenopausal state.

2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;

3. Have medically confirmed ovarian failure.

2. Body Mass Index of 17.5 to 30.5 kg/m2; and a total body weight > 50 kg (110 lbs).

3. Evidence of a personally signed and dated informed consent document indicating that
the subject has been informed of all pertinent aspects of the study.

4. Subjects who are willing and able to comply with all scheduled visits, treatment plan,
laboratory tests, and other study procedures.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Evidence of history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological,
allergic disease (including drug allergies, but excluding untreated, asymptomatic,
seasonal allergies at the time of dosing), cancer, (except for basal cell carcinoma of
skin), erythrocytosis, or seizures.

2. Any condition possibly affecting drug absorption (e.g. gastrectomy).

3. History of bleeding ulcer, bleeding abnormalities or coagulation abnormalities.

4. A positive urine drug screen.

5. Use of tobacco or nicotine-containing products within 3 months of Screening or a
positive urine cotinine test (ie, active smokers and those who currently use
nicotine-containing products are excluded from participation in this study).

6. Significant drug sensitivity or a significant allergic reaction to any drug, as well
as known hypersensitivity or idiosyncratic reaction to epoetin (or its excipients,
including benzyl alcohol and any other related drugs).

7. Any previous use of epoetin.

8. History of regular alcohol consumption exceeding 7 drinks/week for female subjects or
14 drinks/week for male subjects (1 drink = 5 oz. [150 mL] of wine or as oz. [360 mL]
of beer or 1.5 oz. [45 mL] of hard liquor) within 6 months before Screening.

9. Treatment with an investigational drug within 30 days (or as determined by the local
requirement) or 5 half-lives preceeding the fits dose of investigational product
(whichever is longer).

10. Screening supine BP >= 140 mmHg (systolic) or >=90 mmHg (Diastolic), following at
least 5 minutes of supine rest. If BP >= 140 mmHg (systolic) or >= 90 mmHg
(Diastolic), the BP should be repeated 2 more times and the average of the 3 BP values
should be used to determine the subject's eligibility.

11. Screening supine 12-lead ECG demonstrating a corrected QT (QTc) interval> 450 msec or
a QRS interval >120 msec. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG
should be repeated 2 more times and the average of the 3 QTc or QRS values should be
used to determine the subject's eligibility.

12. Subject's with ANY of the following abnormalities in clinical laboratory tests at
Screening, as assessed by the study-specific laboratory and confirmed by a single
repeat test, if deemed necessary:

- Aspartate aminotransferase (AST) OR alanine aminotransferase (ALT) leve l>= 1.5 X
upper limit of normal (ULN);

- Total bilirubin level 1.5 X ULN; subjects with a history of Gilbert's syndrome
may have direct bilirubin measured and would be eligible for this study provided
the direct bilirubin level is

13. Pregnant female subjects; breastfeeding female subjects; fertile male subjects and
female subjects of childbearing potential who are unwilling or unable to use 2 highly
effective methods of contraception as outline in the protocol for the duration of the
study and for at least 30 days after the last dose of investigational product.

14. Use of prescription or nonprescription drugs and dietary supplements within 7 days or
5 half-lives (whichever is longer) prior to the first dose of investigational product.
As exceptions, acetaminophen/paracetamol may be used at doses of hormonal contraceptives will be allowed. Limited use of nonprescription medications
that are not believed to affect subject safety or the overall results of the study may
be permitted on a case-by-case basis following approval by the sponsor.

15. A subject who has been administered a drug by depot injection within 30 days prior to
the initial study drug administration or 6 half-lives of that drug, whichever is
longer and at the discretion of the investigator, or who has received a recent (6
weeks prior to admission to the CRU) live or attenuated vaccination, or exposure to
communicable viral diseases such as chicken pox, varicella, and measles.

16. Blood donation (excluding plasma donations) or approximately 1 pint (500 mL) or more
within 60 days prior to dosing.

17. History of HIV, hepatitis B, or hepatitis C, positive testing for HIV, hepatitis B
surface antigen (HepBsAg), hepatitis B core antibody (HepBcAb), or hepatitis C
antibody (HCVAb).

18. Unwilling or unable to comply with the criteria in the Lifestyle Requirements section
of the protocol.

19. Subjects who are investigator site staff members directly involved in the conduct of
the study and their family members, site staff members otherwise supervised by the
investigator, or subjects who are Pfizer employees, including their family members,
directly involved in the conduct of the study.

20. Other acute or chronic medical or psychiatric condition including recent (within the
past year) or active suicidal ideation or behavior or laboratory abnormality that may
increase the risk associated with study participation or investigational product
administration or may interfere with the interpretation of study results and, in the
judgement of the investigator, would make the subject inappropriate for entry into
this study.

21. May not be able to comply with the requirements of this clinical trial or be able to
communicate effectively with study personnel, or is considered by the investigator,
for any reason, to be an unsuitable candidate for the study.

NCT03398473
Pfizer
Completed
A Study Comparing The Effects Of Epoetin Hospira Single-Dose Vial (SDV) And Multi-Dose Vial (MDV) When Administered Subcutaneously To Normal Healthy Subjects

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
A Study Comparing The Effects Of Epoetin Hospira Single-Dose Vial (SDV) And Multi-Dose Vial (MDV) When Administered Subcutaneously To Normal Healthy Subjects
A Phase 1, Open-label, Randomized, Single Dose, Crossover Study Evaluating The Pharmacokinetics Of Epoetin Following Administration Of Epoetin Hospira Multiple Dose Vial (MDV) Product Compared To Epoetin Hospira Single Dose Vial (SDV) Product As Subcutaneous Injection To Normal Healthy Subjects
This study will assess the PK similarity of epoetin administered as Hospira MDV versus Hospira SDV by conducting a single-dose comparative evaluation in normal healthy subjects enrolled at a single center.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Healthy
  • Drug: Epoetin Hospira SDV
    Epoetin Hospira Single Dose Vial
  • Drug: Epoetin Hospira MDV
    Epoetin Hospira Multi-Dose Vial
  • Experimental: Epoetin Hospira SDV
    Epoetin Hospira Single Dose Vial (SDV)
    Intervention: Drug: Epoetin Hospira SDV
  • Experimental: Epoetin Hospira MDV
    Epoetin Hospira Multi-Dose Vial (MDV)
    Intervention: Drug: Epoetin Hospira MDV
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
68
May 11, 2018
May 11, 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Healthy female and male subjects who, at time of Screening, are between ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination including blood pressure and pulse rate measurement, 12-lead electrocardiogram, or clinical laboratory tests.

    Female subjects of nonchildbearing potential must meet at least 1 of the following criteria:

    1. Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; a serum follicle-stimulating hormone (FSH) level confirming the postmenopausal state.
    2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
    3. Have medically confirmed ovarian failure.
  2. Body Mass Index of 17.5 to 30.5 kg/m2; and a total body weight > 50 kg (110 lbs).
  3. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
  4. Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

  1. Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing), cancer, (except for basal cell carcinoma of skin), erythrocytosis, or seizures.
  2. Any condition possibly affecting drug absorption (e.g. gastrectomy).
  3. History of bleeding ulcer, bleeding abnormalities or coagulation abnormalities.
  4. A positive urine drug screen.
  5. Use of tobacco or nicotine-containing products within 3 months of Screening or a positive urine cotinine test (ie, active smokers and those who currently use nicotine-containing products are excluded from participation in this study).
  6. Significant drug sensitivity or a significant allergic reaction to any drug, as well as known hypersensitivity or idiosyncratic reaction to epoetin (or its excipients, including benzyl alcohol and any other related drugs).
  7. Any previous use of epoetin.
  8. History of regular alcohol consumption exceeding 7 drinks/week for female subjects or 14 drinks/week for male subjects (1 drink = 5 oz. [150 mL] of wine or as oz. [360 mL] of beer or 1.5 oz. [45 mL] of hard liquor) within 6 months before Screening.
  9. Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceeding the fits dose of investigational product (whichever is longer).
  10. Screening supine BP >= 140 mmHg (systolic) or >=90 mmHg (Diastolic), following at least 5 minutes of supine rest. If BP >= 140 mmHg (systolic) or >= 90 mmHg (Diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the subject's eligibility.
  11. Screening supine 12-lead ECG demonstrating a corrected QT (QTc) interval> 450 msec or a QRS interval >120 msec. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTc or QRS values should be used to determine the subject's eligibility.
  12. Subject's with ANY of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study-specific laboratory and confirmed by a single repeat test, if deemed necessary:

    • Aspartate aminotransferase (AST) OR alanine aminotransferase (ALT) leve l>= 1.5 X upper limit of normal (ULN);
    • Total bilirubin level 1.5 X ULN; subjects with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is <= ULN.
  13. Pregnant female subjects; breastfeeding female subjects; fertile male subjects and female subjects of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception as outline in the protocol for the duration of the study and for at least 30 days after the last dose of investigational product.
  14. Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product. As exceptions, acetaminophen/paracetamol may be used at doses of <= 1 g/day and hormonal contraceptives will be allowed. Limited use of nonprescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by the sponsor.
  15. A subject who has been administered a drug by depot injection within 30 days prior to the initial study drug administration or 6 half-lives of that drug, whichever is longer and at the discretion of the investigator, or who has received a recent (6 weeks prior to admission to the CRU) live or attenuated vaccination, or exposure to communicable viral diseases such as chicken pox, varicella, and measles.
  16. Blood donation (excluding plasma donations) or approximately 1 pint (500 mL) or more within 60 days prior to dosing.
  17. History of HIV, hepatitis B, or hepatitis C, positive testing for HIV, hepatitis B surface antigen (HepBsAg), hepatitis B core antibody (HepBcAb), or hepatitis C antibody (HCVAb).
  18. Unwilling or unable to comply with the criteria in the Lifestyle Requirements section of the protocol.
  19. Subjects who are investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
  20. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgement of the investigator, would make the subject inappropriate for entry into this study.
  21. May not be able to comply with the requirements of this clinical trial or be able to communicate effectively with study personnel, or is considered by the investigator, for any reason, to be an unsuitable candidate for the study.
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Yes

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
United States
 
 
NCT03398473
C3461009
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
January 2018

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now